Table 1.
Clinical features between high and low expressions of P4HB for prostate cancer patients in the TCGA database
| Characteristics | P4HB expression | P value | |
|---|---|---|---|
| Low | High | ||
| Sample | 215 | 215 | |
| Age, median (IQR) | 60 (55, 65) | 62 (57, 67) | 0.009 |
| Gleason score, n (%) | < 0.001 | ||
| GS6 | 24 (5.6%) | 15 (3.5%) | |
| GS7 | 122 (28.4%) | 84 (19.5%) | |
| GS8 | 27 (6.3%) | 32 (7.4%) | |
| GS9 | 42 (9.8%) | 84 (19.5%) | |
| T stage, n (%) | 0.002 | ||
| T2 | 92 (21.7%) | 63 (14.9%) | |
| T3 | 118 (27.8%) | 143 (33.7%) | |
| T4 | 1 (0.2%) | 7 (1.7%) | |
| Race, n (%) | 0.271 | ||
| Asian | 8 (1.9%) | 3 (0.7%) | |
| Black or African American | 23 (5.5%) | 27 (6.5%) | |
| White | 176 (42.3%) | 179 (43%) | |
| N stage, n (%) | 0.596 | ||
| N0 | 151 (40.3%) | 155 (41.3%) | |
| N1 | 31 (8.3%) | 38 (10.1%) | |
| Residual tumor, n (%) | 0.008 | ||
| No | 149 (35.6%) | 124 (29.6%) | |
| Yes | 59 (14.1%) | 87 (20.8%) | |
IQR interquartile range